Pluri (PLUR) AI Stock Analysis

• Market Cap: $32.20M
• Dividend Yield: N/A
• Average Volume (3M): 8.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: 121.74%
• EPS Growth: 24.75%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,253,897
• 10 Day Avg. Volume: 13,380
• 30 Day Avg. Volume: 8,388
• PEG Ratio: 1.29
• Price to Book (P/B): -45.85
• Price to Sales (P/S): 234.79
• P/FCF Ratio: -15.82
• Enterprise Value/Market Cap: 1.67
• Enterprise Value/Revenue: 40.60
• Enterprise Value/Gross Profit: 94.62
• Enterprise Value/Ebitda: -2.44
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $3.00 ▼(-13.04% Downside)

The score is driven primarily by weak financial performance (minimal and declining revenue, large losses, heavy cash burn, and negative equity with meaningful debt). Technicals are also unfavorable with a clear downtrend and negative MACD. Valuation is constrained by negative earnings, and the Nasdaq noncompliance notice adds a significant listing-risk overhang.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.

Strategic Partnerships

Strategic partnerships expand Pluri's market reach and provide additional funding, supporting long-term growth and innovation in its product pipeline.

Leadership Incentives

Aligning executive incentives with performance goals can drive strategic decision-making and improve operational efficiency, benefiting long-term company performance.

Negative Factors

Financial Instability

Financial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow indicates ongoing operational challenges, which may hinder Pluri's ability to sustain operations and invest in future growth without additional financing.

Profitability Challenges

Ongoing profitability challenges with negative margins suggest difficulty in achieving sustainable earnings, impacting long-term financial health and investor confidence.

Pluri Business Overview & Revenue Model

Company Description

Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.

How the Company Makes Money

Pluri generates revenue through multiple streams, primarily by commercializing its proprietary technologies and cell therapy products. The company licenses its technology to pharmaceutical and biotechnology firms, which pay upfront fees and ongoing royalties based on sales of products developed using Pluri's platform. Additionally, Pluri engages in strategic partnerships and collaborations with research institutions and healthcare organizations, which often include funding arrangements for joint research projects. The company may also generate revenue from grants and funding from government and non-profit organizations aimed at supporting innovative medical research. Overall, Pluri's revenue model is driven by the successful development and commercialization of cutting-edge therapies, along with strategic collaborations that enhance its market reach.

Pluri Financial Statement Overview

Summary

Financials are very weak: TTM revenue is small (~$1.3M) and down sharply, losses are large (net loss ~-$22.8M), and cash burn remains heavy (FCF ~-$21.1M). The biggest risk is a stressed balance sheet with negative equity (~-$11.4M) alongside sizable debt (~$34.2M), increasing solvency and financing/dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is modest at ~$1.3M and declined sharply (down ~75% vs. the prior period shown), while profitability remains deeply negative (net loss ~-$22.8M; net margin ~-1,722%). Gross margin is positive (~43%) but far from covering the fixed cost base, as operating losses remain very large (EBIT ~-$23.4M). Overall, the business shows limited scale and persistent, outsized losses despite some improvement versus earlier years’ extreme margins.

Balance Sheet

The balance sheet is stressed: stockholders’ equity is negative in TTM (about -$11.4M), which is a major red flag and implies a thin capital cushion. Total debt is high relative to the company’s size (about $34.2M), and leverage metrics are distorted by negative equity (debt-to-equity is negative). Total assets are ~$33.7M, but the combination of negative equity and continued losses elevates financing and solvency risk.

Cash Flow

Cash burn remains heavy: TTM operating cash flow is about -$19.6M and free cash flow about -$21.1M, indicating the business is not self-funding. Free cash flow is slightly better than net income (free cash flow to net income ~1.08), suggesting meaningful non-cash charges, but that does not change the core issue that cash outflows are persistent. Free cash flow growth is positive in TTM, yet absolute burn is still substantial.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33M	1.34M	326.00K	287.00K	234.00K	0.00
Gross Profit	569.00K	654.00K	322.00K	278.00K	-819.00K	-1.37M
EBITDA	-22.09M	-22.07M	-20.23M	-27.68M	-39.43M	-48.42M
Net Income	-22.83M	-22.58M	-20.89M	-28.32M	-41.24M	-49.87M
Balance Sheet
Total Assets	33.67M	38.68M	39.53M	50.80M	68.06M	93.54M
Cash, Cash Equivalents and Short-Term Investments	15.06M	20.61M	30.24M	40.17M	55.02M	64.95M
Total Debt	34.24M	34.05M	29.61M	29.91M	28.80M	24.58M
Total Liabilities	39.32M	39.55M	34.11M	35.50M	35.88M	36.39M
Stockholders Equity	-11.36M	-6.84M	96.00K	13.36M	30.04M	57.15M
Cash Flow
Free Cash Flow	-21.10M	-19.83M	-18.34M	-23.12M	-36.78M	-31.28M
Operating Cash Flow	-19.57M	-18.21M	-18.02M	-22.86M	-36.50M	-30.91M
Investing Cash Flow	11.29M	8.03M	10.58M	9.70M	11.78M	-7.26M
Financing Cash Flow	9.53M	9.53M	8.84M	8.02M	7.50M	61.40M

Pluri Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.45
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Neutral. The current price of 3.45 is above the 20-day moving average (MA) of 3.17, above the 50-day MA of 3.27, and below the 200-day MA of 4.35, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 74.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56 Neutral	$72.81M	-1.63	-390.53%	―	―	61.23%
ANTX	52 Neutral	$30.96M	-0.99	-45.91%	―	―	44.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IGC	47 Neutral	$25.87M	-3.52	-83.34%	―	-6.51%	58.31%
ITRM	43 Neutral	$16.22M	-0.45	―	―	―	62.61%
PLUR	40 Underperform	$32.20M	-1.07	―	―	121.74%	24.75%

Pluri Corporate Events

Pluri Faces Nasdaq Noncompliance Notice, Evaluating Listing Options

On January 20, 2026, Pluri Inc. disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s continued listing standards, having fallen below the required $35 million market value of listed securities and failing to meet alternative thresholds for stockholders’ equity or net income. The notice does not immediately affect trading of Pluri’s shares, but the company has 180 days, until July 20, 2026, to regain compliance by lifting its market value above the required level for a sustained period, after which it could face delisting unless it successfully appeals; Pluri said it is evaluating options to restore compliance, leaving investors facing heightened uncertainty over its Nasdaq listing status.

The most recent analyst rating on (PLUR) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Grants RSUs to Executives and Board Members

On December 4, 2025, Pluri‘s board of directors granted a total of 10,248 restricted stock units (RSUs) to its Chief Executive Officer and Chief Financial Officer, and 2,885 RSUs to board members as part of its 2019 Equity Compensation Plan. This move aims to support cost-management initiatives and align leadership incentives with long-term performance goals. Additionally, Mr. Weinstein was appointed as Chairman of the Board, and Mr. Zami Aberman as Vice Chairman, with Mr. Aberman’s consultancy agreement set to terminate on January 4, 2026.

The most recent analyst rating on (PLUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.